Effects of phosphate binders in moderate CKD - Wikidata - wikimedia - TriplyDB

Effects of phosphate binders in moderate CKD

Effects of phosphate binders in moderate CKD

http://www.wikidata.org/entity/Q36109201

about

Fibroblast growth factor 23 Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence Vascular calcification--is aldosterone a culprit?Phosphate control in end-stage renal disease: barriers and opportunities Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherence FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.Vascular calcification: When should we interfere in chronic kidney disease patients and how?Stop chronic kidney disease progression: Time is approaching The Role of Emerging Risk Factors in Cardiovascular Outcomes High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III.Phosphate binders in chronic kidney disease: a systematic review of recent data.Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4 Calcium Balance in Chronic Kidney Disease.Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D The use of fibroblast growth factor 23 testing in patients with kidney disease.Calcium balance and negative impact of calcium load in peritoneal dialysis patients.Phosphate metabolism modulation in chronic kidney disease: when, how and to what extent?Effect of niacin on FGF23 concentration in chronic kidney disease.Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial VS-501: A NOVEL, NON-ABSORBED, CALCIUM- AND ALUMINUM-FREE, HIGHLY EFFECTIVE PHOSPHATE BINDER DERIVED FROM NATURAL PLANT POLYMER Serum phosphorus and mortality in the Third National Health and Nutrition Examination Survey (NHANES III): effect modification by fasting.Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease.Calcium supplementation increases blood creatinine concentration in a randomized controlled trial.Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective.Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.Hyperphosphate-Induced Myocardial Hypertrophy through the GATA-4/NFAT-3 Signaling Pathway Is Attenuated by ERK Inhibitor Treatment.Management of hyperphosphataemia in chronic kidney disease-challenges and solutions Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.The demise of calcium-based phosphate binders-is this appropriate for children?

P2860

Q26829294-B568CDE9-6C5C-4ABF-92A9-74FE0E2D5526 Q26830013-0ED198B4-1F96-4898-B90A-5D0A91967CE8 Q26851687-3A1EFBB0-544F-4B41-9570-00D894F88CDA Q26853372-CF75520E-0C6A-435A-9C89-A9D2AFC187EF Q26863412-1AF676D9-93A1-46F3-AD49-C788A5635280 Q27002431-8406BC55-AB0F-4033-A21A-AE058E323527 Q27013882-C080EF21-08DA-42F8-8EAB-6DA083899E44 Q27687769-1915AE58-3711-44DB-B86F-92A18E3EA266 Q28071582-3CAB0F08-B25B-4765-A07C-A4DFB885DCE1 Q28078020-20AB4E34-9A51-46C4-BE03-3A0C3CC3AA2B Q30234550-3772AD42-F0CC-4ECE-B11D-4FFA8DE45B0E Q30564821-5670E130-1356-4D82-816C-6D5DAEEB8420 Q31039292-2A2E33FA-3172-43D9-93F6-185CC781DFDF Q33432308-9DB74815-2EF6-490E-B128-5E7819FFAB69 Q33571829-7ADB7271-E352-48A3-BA79-9EAFAF6931D1 Q33643233-99D37483-4459-4C43-872F-77C4EB0C6EBC Q33715785-D5BBDE84-2CCF-4EF9-BD36-6E41674E8A65 Q33720411-58865BC4-1866-4FCB-8D33-AF2636305E97 Q33801022-34C40C16-1F04-4926-B26F-FC082D2E9354 Q33835743-035D6A6A-5936-4A44-8624-CC424B3F96DD Q33837633-61092726-25FA-4A15-82EE-F21726991718 Q33877167-89165022-96DB-4D96-B6EC-671AC05B7974 Q33914268-62CB9023-39E0-454F-9783-A97B6930FA5A Q33937415-3DC4F273-573D-487F-92FF-3D7218A6FDE1 Q34120727-FB2E42F5-0943-4E49-8800-88EB0C88651E Q34254746-0ECEEC7A-C1EF-46FE-9DDC-F0B9514A429C Q34336027-FF2A2C50-9F83-452C-92B0-4FBEABAA3A4A Q34337575-136B50BE-47A3-4CA0-80FF-91B7CFD05BA9 Q34343449-26EA340F-21C9-409A-BAE0-7B9F66412186 Q34415635-7054B26A-4067-45E9-A7A4-323DFD18FEA5 Q34505136-35CC164D-8722-440A-9803-BF686AEC012E Q35218508-04225520-52A9-4CA5-8B84-A3885A6BFB2E Q35550601-DCC67089-CDC7-4018-9AA0-C43230867978 Q35592504-53BDE58F-6283-4C90-87D0-B51E2D819816 Q35608435-10ECAD22-0722-4B73-A21A-52CD92C39A4A Q35682152-DD672659-7CD5-4049-8D62-A26C3F04E520 Q35997370-CB686D73-35FE-4F7B-9B36-DF130F96ECA5 Q36045060-9EEC437E-192D-40B7-B714-970C10A3F733 Q36104887-80890D71-2625-44DE-9C05-25C27880C5B2 Q36214854-E476F6FE-4453-47C0-919E-5219E976C7CD

P2860

Effects of phosphate binders in moderate CKD

http://www.wikidata.org/entity/Q36109201

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effects of phosphate binders in moderate CKD

@ast

Effects of phosphate binders in moderate CKD

@en

type

label

Effects of phosphate binders in moderate CKD

@ast

Effects of phosphate binders in moderate CKD

@en

prefLabel

Effects of phosphate binders in moderate CKD

@ast

Effects of phosphate binders in moderate CKD

@en

P1433

Q36109201-0F557305-091D-4560-8D52-BC5119E5023C

P1476

Q36109201-25698F58-AD6C-4756-AEA8-D734EC9DB763

P2093

Q36109201-3267F27D-149B-4BCF-968C-36A30E5A7227

Q36109201-A9FD8BEC-64C0-422B-B883-101BF1FDF6C7

Q36109201-D02900EC-5DBD-444C-AD95-41A7D457E0EF

Q36109201-D55CFA85-5A38-4D8C-A320-4AD6637CDE69

Q36109201-DE764A93-87A8-47A3-A99D-D1890154C276

Q36109201-DEB2048B-1AEC-4856-8F6A-13AEC40F037B

Q36109201-EB6824DD-48C6-4CC6-9B9C-E11C51E5642C

Q36109201-EE6E033A-59E1-4DB8-9882-710D476705C3

Q36109201-F2D1A544-D8E0-47F1-9A58-177F9ADCE158

Q36109201-F4D0ADD5-2938-4F38-9101-B4F1069B3C85

P2860

Q36109201-01E25794-198A-4A10-AFA6-70BC4715B7C9

Q36109201-067373E5-260F-41CA-A768-2CE6DE01A11A

Q36109201-111401B2-3049-4F01-876D-4485ADCA37D2

Q36109201-23BAEC4A-E73F-46AA-87E1-390C32F97A65

Q36109201-339D41F1-9024-4507-BEA6-DFCDB501D7E8

Q36109201-33BCAC20-AA9C-46F8-846C-F2C0DD1965B7

Q36109201-376B3314-A277-484D-A8CF-6B63C063C62C

Q36109201-593760F4-78D1-4213-9A65-73C5B5C27780

Q36109201-66225B2A-2B27-47A1-A11C-904C4045B0ED

Q36109201-79C43AFE-FB91-4ABC-977E-F260407426DC

P304

Q36109201-7C11119F-0330-4BB4-A01C-32D429891A4A

P31

Q36109201-0594F522-98AC-487F-9E2C-42ACFC6E0193

P356

Q36109201-342D0801-769E-4F4A-8950-F08428B16334

P433

Q36109201-D1A5488F-CA0A-4D30-9DE8-DCA2BD87B597

P478

Q36109201-DD28FA6E-D07B-4516-AACA-233A9FD95962

P50

Q36109201-48986F2B-C5E1-4585-B58D-45002C1F6214

Q36109201-7EDF7768-0B74-4D96-A694-1CCDD1EF0C6B

Q36109201-BA4F38FB-8CDB-4FF5-BD12-F784A40D3058

P577

Q36109201-3898EC01-BA04-4747-9DFE-FE9391EA9D42

P698

Q36109201-1F948709-F5D6-4216-AE99-0690E3ECBAA6

P932

Q36109201-2B094277-C484-4277-A37F-494BA8BB761D

P356

P1433

Journal of the American Society of Nephrology

P1476

Effects of phosphate binders in moderate CKD

@en

P2093

David C Wheeler

http://www.w3.org/2001/XMLSchema#string

David M Spiegel

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Block

http://www.w3.org/2001/XMLSchema#string

Gerard Smits

http://www.w3.org/2001/XMLSchema#string

Glenn M Chertow

http://www.w3.org/2001/XMLSchema#string

John Asplin

http://www.w3.org/2001/XMLSchema#string

Laura Kooienga

http://www.w3.org/2001/XMLSchema#string

Markus Ketteler

http://www.w3.org/2001/XMLSchema#string

Martha S Persky

http://www.w3.org/2001/XMLSchema#string

Michael Mannstadt

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD

Intestinal npt2b plays a major role in phosphate absorption and homeostasis.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease

FGF23 induces left ventricular hypertrophy

Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study.

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.

Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D

P304

1407-1415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2012030223

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Matthew Allison

Andrew N Hoofnagle

Bryan R Kestenbaum

P577

2012-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22822075

http://www.w3.org/2001/XMLSchema#string

P932

3402292

http://www.w3.org/2001/XMLSchema#string